Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$483.00 USD

483.00
2,259,829

-15.73 (-3.15%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $224.17, moving +0.06% from the previous trading session.

Kevin Cook headshot

CRISPR Gene Editing: Owning the Future of Medicine

by Kevin Cook

In the Century of Biology, it pays to own the future of curing disease at the root.

Editas (EDIT) Submits Application to Start Study on EDIT-301

by Zacks Equity Research

Editas (EDIT) files an IND application to the FDA for beginning a phase I/II study of EDIT-301 to treat SCD.

Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News

by Zacks Equity Research

Data readouts at ASH take centerstage in the biotech sector as Fate (FATE) and CRISPR (CRSP) among others provide key updates.

CRISPR (CRSP) Up on Promising Data for Gene Therapy CTX001

by Zacks Equity Research

CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows sustained response to treatment in patients with transfusion-dependent beta thalassemia as well as sickle cell disease. Shares rise.

Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More

by Zacks Equity Research

Collaborations, and pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and BioNTech (BNTX) provide key updates.

Vertex (VRTX) Symkevi/Kalydeco Label Expansion Gets EU Nod

by Zacks Equity Research

Vertex (VRTX) gets European approval for label expansion of Symkevi and Kalydeco combination pill in cystic fibrosis patients aged six to 11.

Is a Beat in Store for Royalty Pharma (RPRX) in Q3 Earnings?

by Zacks Equity Research

Some of the drugs under Royalty Pharma's (RPRX) royalty acquisition agreements performed well during the third quarter while others declined or flatlined.

Biotech Stock Roundup: Gilead, Amgen, Vertex and Alexion Report Q3 Earnings & More

by Zacks Equity Research

Third-quarter earnings take centerstage in the biotech sector as Gilead (GILD), Amgen (AMGN) and others report results.

Moderna (MRNA) Q3 Earnings Lag Estimates, Pipeline Advances

by Zacks Equity Research

Moderna (MRNA) reports wider-than-expected third-quarter loss. However, revenues beat estimates significantly. Shares up presumably on encouraging pipeline progress and rising cash resources.

Vertex (VRTX) Beats on Q3 Earnings & Sales, Ups Sales View

by Zacks Equity Research

Vertex (VRTX) beats estimates for both earnings and sales and raises revenue guidance for 2020.

Vertex Pharmaceuticals (VRTX) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Vertex (VRTX) delivered earnings and revenue surprises of 10.46% and 3.38%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Can Coronavirus Vaccine Efforts Aid Novavax (NVAX) Q3 Earnings?

by Zacks Equity Research

During Novavax's (NVAX) upcoming third-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.

What's in Store for ADMA Biologics' (ADMA) Q3 Earnings?

by Zacks Equity Research

On ADMA Biologics' (ADMA) third-quarter earnings call, investor focus will be on the sales performance of its newly approved immunoglobulin products, Asceniv and Bivigam.

Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus is likely to be on any update on the timeline for filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the third-quarter earrings call.

Mattel, PLCE, Gilead, Vertex and Horizon as Zacks Bull and Bear of the Day

by Zacks Equity Research

Mattel, PLCE, Gilead, Vertex and Horizon as Zacks Bull and Bear of the Day

What's in the Cards for Cassava (SAVA) This Earnings Season?

by Zacks Equity Research

Investors will be keen on updates from the recent study on its lead candidate, sumifilam, when Cassava (SAVA) reports Q3 results.

Can Trikafta Drive Vertex's (VRTX) Revenues in Q3 Earnings?

by Zacks Equity Research

On Vertex's (VRTX) third-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta and the probable impact of COVID-19 on the same.

Will Coronavirus Woes Affect Gilead's (GILD) Q3 Earnings?

by Zacks Equity Research

Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on experimental coronavirus treatment, when Gilead (GILD) reports third-quarter 2020 results.

CRISPR (CRSP) Falls Despite Positive Data on Lymphoma Study

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reports top-line data from a phase I study, currently evaluating its pipeline candidate CTX110 for CD19+ B-cell malignancies. Shares down.

Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates

by Zacks Equity Research

The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.

AstraZeneca's (AZN) Tagrisso sNDA Receives Priority Review

by Zacks Equity Research

AstraZeneca's (AZN) regulatory application for label expansion of Tagrisso to include adjuvant treatment of patients with early-stage EGFR-mutated lung cancer gets FDA's apriority review.

Zacks.com featured highlights include: Meritage Homes, Vertex Pharmaceuticals, CVS Health, Amedisys and Insperity

by Zacks Equity Research

Zacks.com featured highlights include: Meritage Homes, Vertex Pharmaceuticals, CVS Health, Amedisys and Insperity

Zacks.com featured highlights include: Vertex Pharmaceuticals, PerkinElmer, Stanley Black & Decker, 3M and Arthur J. Gallagher & Co

by Zacks Equity Research

Zacks.com featured highlights include: Vertex Pharmaceuticals, PerkinElmer, Stanley Black & Decker, 3M and Arthur J. Gallagher & Co